欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2024, Vol. 29 ›› Issue (4): 427-431.doi: 10.12092/j.issn.1009-2501.2024.04.010

• 慢性气道疾病药物治疗新进展 • 上一篇    下一篇

过敏原特异性免疫治疗在过敏性气道疾病中的应用进展

王林林,马圆,陈智鸿,计海婴   

  1. 复旦大学附属中山医院呼吸与危重症医学科,上海  200032
  • 收稿日期:2023-10-08 修回日期:2024-01-31 出版日期:2024-04-26 发布日期:2024-03-25
  • 通讯作者: 计海婴,女,硕士,主治医师,主要研究方向:呼吸危重症及慢性气道病。 E-mail: ji.haiying@zs-hospital.sh.cn
  • 作者简介:王林林,女,博士,主治医师,主要研究方向:急性肺损伤和肺部感染及慢性气道性疾病。 E-mail: siyuxueer@163.com
  • 基金资助:
    国家自然科学基金(82000087);国家自然科学基金(82270026)

Progress in the application of AIT in allergic airway diseases

WANG Linlin, MA Yuan, CHEN Zhihong, JI Haiying    

  1. Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China
  • Received:2023-10-08 Revised:2024-01-31 Online:2024-04-26 Published:2024-03-25

摘要:

过敏原特异性免疫治疗(allergen immunotherapy,AIT)是明确患者过敏原后,给患者反复接触过敏原提取物,并逐渐增加浓度和剂量直到达到目标维持剂量,从而使患者对过敏原产生耐受,这是至今惟一一种可以调控变应性疾病发病机制进而改变其自然进程的治疗方法。近年来国内外学者在AIT临床实践和研究领域均取得较大进展,本文对AIT的作用机制、疗效和给药途径等研究进展进行概述。

关键词: 过敏原特异性免疫治疗, 过敏性哮喘, 过敏性鼻炎

Abstract:

Allergen specific immunotherapy (AIT) is to identify the patient's allergen, give the patient repeated exposure to the allergen extract, and gradually increase the concentration and dose until the target maintenance dose is reached, so that the patient can develop tolerance to the allergen, which is the only treatment that can regulate the pathogenesis of allergic diseases and change its natural course. In recent years, domestic and foreign scholars have made great progress in the clinical practice and research field of AIT. This article reviewed the relevant progress of the mechanism, efficacy and drug administration of AIT.

Key words: allergen immunotherapy, allergic asthma, allergic rhinitis

中图分类号: